A Risk Management Plan is not a formality appended to a dossier. It is the document in which you commit, in writing, to how a product’s risks will be identified, characterised and minimised for the rest of its life.
RMPs are governed by GVP Module V, and the risk management system must be proportionate to the identified risks — a principle that cuts both ways. Over-engineering an RMP creates obligations you must then honour; under-engineering it invites regulatory challenge.
The structure
The EU RMP has seven parts:
- Part I — Product overview.
- Part II — Safety specification, built from modules SI to SVIII: epidemiology, non-clinical data, clinical trial exposure, populations not studied, post-authorisation experience, additional EU requirements, identified and potential risks, and the summary of safety concerns.
- Part III — Pharmacovigilance plan.
- Part IV — Post-authorisation efficacy studies.
- Part V — Risk minimisation measures.
- Part VI — Summary of the RMP.
- Part VII — Annexes.
Routine versus additional measures
The product information is the key routine risk minimisation tool, alongside pack size, legal status and prescription controls. Additional measures — educational materials, controlled access programmes, pregnancy prevention programmes — carry a heavier burden: their effectiveness must be evaluated and reported, in Part V of the RMP and in the relevant PSUR section.
A nuance most people still get wrong
It is widely believed that the safety concerns listed in the RMP and the PSUR must match. Since GVP Module V Rev. 2 that has not been a requirement, and current EMA guidance is explicit that the two lists might legitimately differ — because Module V’s definitions apply in the context of risk management planning, based on benefit-risk impact and the need for further risk minimisation. Aligning them mechanically can be the wrong answer.
When to update
An RMP must be updated at the request of the EMA or a national authority, and whenever the risk management system is modified — particularly on new information that may significantly change the benefit-risk profile, or on reaching an important pharmacovigilance or risk minimisation milestone. Note too that an RMP may only be submitted alongside a PSUR where the change is a consequence of that PSUR.
Transparency
Since October 2023 the EMA publishes full RMPs for centrally authorised products rather than summaries. Your RMP is a public document — write it accordingly.
How PQRA helps
PQRA authors and maintains RMPs, designs and evaluates additional risk minimisation measures, and keeps your commitments deliverable.
No responses yet